Wells Fargo & Company Issues Positive Forecast for Enovis (NYSE:ENOV) Stock Price

Enovis (NYSE:ENOV) had its target price upped by Wells Fargo & Company from $41.00 to $42.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages have also recently commented on ENOV. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. UBS Group dropped their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Needham & Company LLC reduced their target price on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group dropped their price target on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average target price of $51.17.

Enovis Price Performance

NYSE:ENOV traded down $0.41 during trading hours on Friday, hitting $28.02. The company’s stock had a trading volume of 1,092,886 shares, compared to its average volume of 1,104,868. Enovis has a 52-week low of $25.47 and a 52-week high of $49.75. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. The business’s 50-day moving average is $31.33 and its two-hundred day moving average is $31.48. The company has a market capitalization of $1.60 billion, a PE ratio of -1.97 and a beta of 1.67.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $383.81 million during the quarter. As a group, research analysts anticipate that Enovis will post 2.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Damien Mcdonald acquired 6,457 shares of the business’s stock in a transaction dated Thursday, September 11th. The shares were acquired at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the acquisition, the chief executive officer directly owned 102,753 shares in the company, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was bought at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the transaction, the chief financial officer directly owned 116,729 shares of the company’s stock, valued at approximately $3,468,018.59. The trade was a 2.19% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 12,157 shares of company stock worth $374,760. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enovis

A number of large investors have recently bought and sold shares of the stock. US Bancorp DE increased its stake in Enovis by 2.5% during the first quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after acquiring an additional 462 shares during the last quarter. Central Valley Advisors LLC grew its holdings in shares of Enovis by 18.5% during the 2nd quarter. Central Valley Advisors LLC now owns 57,372 shares of the company’s stock worth $1,799,000 after purchasing an additional 8,951 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Enovis during the 1st quarter worth about $537,000. Simon Quick Advisors LLC acquired a new stake in Enovis during the 2nd quarter worth approximately $251,000. Finally, Lawson Kroeker Investment Management Inc. NE raised its holdings in Enovis by 6.3% in the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 227,235 shares of the company’s stock valued at $7,126,000 after buying an additional 13,566 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.